SHTDF (Sinopharm Group Co) Accumulated Depreciation : $-2,441 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Sinopharm Group Co's quarterly accumulated depreciation declined from Dec. 2023 ($-2,220 Mil) to Jun. 2024 ($0 Mil) but then increased from Jun. 2024 ($0 Mil) to Dec. 2024 ($-2,441 Mil).

Sinopharm Group Co's annual accumulated depreciation increased from Dec. 2022 ($-2,049 Mil) to Dec. 2023 ($-2,220 Mil) and increased from Dec. 2023 ($-2,220 Mil) to Dec. 2024 ($-2,441 Mil).

Sinopharm Group Co Accumulated Depreciation Historical Data

The historical data trend for Sinopharm Group Co's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Accumulated Depreciation Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-1,507.35

-1,903.87

-2,049.46

-2,219.77

-2,440.94

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accumulated Depreciation	Get a 7-Day Free Trial															-2,049.46	-	-2,219.77	-	-2,440.94

Sinopharm Group Co Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Sinopharm Group Co Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

SHTDY:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research • 06-17-2024

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020